Cargando…

Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells

Introduction: Cyclin D1 (D1) binds to cyclin-dependent kinases (CDK) 4 or 6 to form a holoenzyme that phosphorylates the Rb protein to promote cell cycle progression from G1 to S phase. Therefore, targeting CDK4/6 may be a good strategy for chemotherapy of cancer. We performed a proof-of-principle s...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yuan, Li, Ying-xia, Wu, Hai-jun, Wu, Si-hung, Wang, Y. Alan, Luo, Dian-zhong, Liao, D. Joshua
Formato: Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020360/
https://www.ncbi.nlm.nih.gov/pubmed/21234300
_version_ 1782196300453773312
author Sun, Yuan
Li, Ying-xia
Wu, Hai-jun
Wu, Si-hung
Wang, Y. Alan
Luo, Dian-zhong
Liao, D. Joshua
author_facet Sun, Yuan
Li, Ying-xia
Wu, Hai-jun
Wu, Si-hung
Wang, Y. Alan
Luo, Dian-zhong
Liao, D. Joshua
author_sort Sun, Yuan
collection PubMed
description Introduction: Cyclin D1 (D1) binds to cyclin-dependent kinases (CDK) 4 or 6 to form a holoenzyme that phosphorylates the Rb protein to promote cell cycle progression from G1 to S phase. Therefore, targeting CDK4/6 may be a good strategy for chemotherapy of cancer. We performed a proof-of-principle study to determine the effect of Naphtho [2, 1-α] pyrrolo [3, 4-c] carbazole-5, 7 (6H, 12H)-dione (NPCD), a novel CDK4 inhibitor, on breast cancer cell lines. Methods: NPCD was synthesized and purified to over 99% purity verified by HPLC. MCF7, MB231, MCF15, T47D and GI101Ap human breast cancer cells were analyzed for the efficacy of NPCD with MTT and clonogenic assays, with FACS and staining for ethidium bromide and acridine orange for cell death and cell cycle profile. Western blot, reverse transcription and PCR were used for studies of gene expression, and co-immunoprecipitation for protein-complex formation. Results: MTT assay showed that NPCD caused growth arrest and apoptosis of MCF7, MDA-MB231, T47D, MCF15 and GI101Ap cells with an IC50 ranging between 3 to 8 µM given as a single dose. The growth arrest persisted for many days after cessation of the treatment, as shown in a clonogenic assay. NPCD could induce or reduce the D1 and CDK4 protein levels, depending on the cell line, but this effect was not correlated with its efficacy. Phosphorylation of D1 at Thr286 was decreased but it unexpectedly did not correlate with the change in D1 level in the cell lines studied. Phosphorylation of the Rb protein was decreased as expected whereas the p27kip1 protein level was decreased unexpectedly. Protein levels of p21cip1, CDK2 and cyclin E were also decreased in some, but not all, of the cell lines, whereas the mRNA levels of D1, CDK4, cyclin E, CDK2, p27kip1 and p21cip1 were increased in different cell lines. Conclusions: NPCD can cause long-lasting growth arrest and cell death of breast cancer cell lines at an IC50 of 3-8 µM. Decreased phosphorylation of Rb by D1-CDK4/6 and decreased p27kip1 protein level may be part of the underlying mechanism.
format Text
id pubmed-3020360
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-30203602011-01-13 Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells Sun, Yuan Li, Ying-xia Wu, Hai-jun Wu, Si-hung Wang, Y. Alan Luo, Dian-zhong Liao, D. Joshua J Cancer Research Paper Introduction: Cyclin D1 (D1) binds to cyclin-dependent kinases (CDK) 4 or 6 to form a holoenzyme that phosphorylates the Rb protein to promote cell cycle progression from G1 to S phase. Therefore, targeting CDK4/6 may be a good strategy for chemotherapy of cancer. We performed a proof-of-principle study to determine the effect of Naphtho [2, 1-α] pyrrolo [3, 4-c] carbazole-5, 7 (6H, 12H)-dione (NPCD), a novel CDK4 inhibitor, on breast cancer cell lines. Methods: NPCD was synthesized and purified to over 99% purity verified by HPLC. MCF7, MB231, MCF15, T47D and GI101Ap human breast cancer cells were analyzed for the efficacy of NPCD with MTT and clonogenic assays, with FACS and staining for ethidium bromide and acridine orange for cell death and cell cycle profile. Western blot, reverse transcription and PCR were used for studies of gene expression, and co-immunoprecipitation for protein-complex formation. Results: MTT assay showed that NPCD caused growth arrest and apoptosis of MCF7, MDA-MB231, T47D, MCF15 and GI101Ap cells with an IC50 ranging between 3 to 8 µM given as a single dose. The growth arrest persisted for many days after cessation of the treatment, as shown in a clonogenic assay. NPCD could induce or reduce the D1 and CDK4 protein levels, depending on the cell line, but this effect was not correlated with its efficacy. Phosphorylation of D1 at Thr286 was decreased but it unexpectedly did not correlate with the change in D1 level in the cell lines studied. Phosphorylation of the Rb protein was decreased as expected whereas the p27kip1 protein level was decreased unexpectedly. Protein levels of p21cip1, CDK2 and cyclin E were also decreased in some, but not all, of the cell lines, whereas the mRNA levels of D1, CDK4, cyclin E, CDK2, p27kip1 and p21cip1 were increased in different cell lines. Conclusions: NPCD can cause long-lasting growth arrest and cell death of breast cancer cell lines at an IC50 of 3-8 µM. Decreased phosphorylation of Rb by D1-CDK4/6 and decreased p27kip1 protein level may be part of the underlying mechanism. Ivyspring International Publisher 2011-01-08 /pmc/articles/PMC3020360/ /pubmed/21234300 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
spellingShingle Research Paper
Sun, Yuan
Li, Ying-xia
Wu, Hai-jun
Wu, Si-hung
Wang, Y. Alan
Luo, Dian-zhong
Liao, D. Joshua
Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells
title Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells
title_full Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells
title_fullStr Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells
title_full_unstemmed Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells
title_short Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells
title_sort effects of an indolocarbazole-derived cdk4 inhibitor on breast cancer cells
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020360/
https://www.ncbi.nlm.nih.gov/pubmed/21234300
work_keys_str_mv AT sunyuan effectsofanindolocarbazolederivedcdk4inhibitoronbreastcancercells
AT liyingxia effectsofanindolocarbazolederivedcdk4inhibitoronbreastcancercells
AT wuhaijun effectsofanindolocarbazolederivedcdk4inhibitoronbreastcancercells
AT wusihung effectsofanindolocarbazolederivedcdk4inhibitoronbreastcancercells
AT wangyalan effectsofanindolocarbazolederivedcdk4inhibitoronbreastcancercells
AT luodianzhong effectsofanindolocarbazolederivedcdk4inhibitoronbreastcancercells
AT liaodjoshua effectsofanindolocarbazolederivedcdk4inhibitoronbreastcancercells